Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate

Published on : Published by : BioBuzz Media

Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company’s investigational universal influenza vaccine candidate. This current version of Emergent’s universal influenza vaccine candidate contains multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses.

Gaithersburg’s Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems

Published on : Published by : BioBuzz Media

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Novavax’ recombinant nanoparticle protein vaccine candidate is being studied in OCTAVE-DUO, now underway in the UK to evaluate the safety and immunogenicity of a third COVID-19 vaccine dose in participants with impaired immune systems.

Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility

Published on : Published by : BioBuzz Media

Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview manufacturing facility to resume production of Johnson & Johnson’s (J&J) Covid-19 vaccine bulk drug substance. This resumption of manufacturing follows extensive reviews by FDA, weeks of diligent work, and close coordination with J&J and FDA to execute on Emergent’s quality enhancement plan.

The Storied 25 Year History Behind the Baltimore Biotech Manufacturing Facility Producing COVID-19 Vaccines

Published on : Published by : Alex Keown

Emergent Biosolutions’ vaccine manufacturing plant in Baltimore has been the subject of many headlines this past year for its’ role in producing several COVID-19 Vaccines.  However, the history of this facility goes back more than two decades.

UAB: Altimmune’s Intranasal COVID Vaccine Candidate Shows Sterilizing Immunity in Preclinical Tests

Published on : Published by : BioBuzz Media

University of Alabama at Birmingham researchers report additional preclinical evidence of the potency of a single-dose, intranasal COVID-19 vaccine candidate – AdCOVID – that was created by Altimmune Inc., a Maryland-based clinical-stage biopharmaceutical company.

Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus, Virus-Like Particle Vaccine Candidate

Published on : Published by : BioBuzz Media

Emergent BioSolutions Inc. (NYSE:EBS) announced two-year persistence data from its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate in 415 healthy adults.

Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine

Published on : Published by : BioBuzz Media

Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine Canadian government commits to purchase 52 million doses with option for additional 24 million of Novavax candidate vaccine, [….]

Novavax taps Baxter for commercial production as COVID-19 vaccine nears finish line

Published on : Published by : BioBuzz Media

Novavax tapped Baxter BioPharma Solutions to support commercial-scale vaccine manufacturing at its facility in Halle, Germany. Once manufacturing work kicks off, Baxter will be on deck to crank out supplies for the European and U.K. markets, the companies said.